306 related articles for article (PubMed ID: 4729314)
21. Clinical evaluation of an innoxious antineoplastic agent: preliminary study of 106 patients treated with or without RSV after pulmonary resection for bronchogenic carcinoma.
Hansen JL
Cancer Chemother Rep 3; 1973 Mar; 4(2):261-4. PubMed ID: 4729327
[No Abstract] [Full Text] [Related]
22. [On ''Multimodal treatment of clinical non-small cell N2 bronchogenic carcinoma: what is the answer?''].
González Aragoneses F
Arch Bronconeumol; 2007 Mar; 43(3):183-4; author reply 184. PubMed ID: 17386198
[No Abstract] [Full Text] [Related]
23. Management of small-cell bronchogenic carcinoma.
Holoye PY
Compr Ther; 1978 Feb; 4(2):35-41. PubMed ID: 414876
[No Abstract] [Full Text] [Related]
24. [Sequential polychemotherapeutic treatment of inoperable bronchogenic carcinoma].
Rambotti P; Allegra A; Soldani M; Aversa F; Colozza M; Liberati M
Clin Ter; 1979 Apr; 89(2):151-62. PubMed ID: 487713
[No Abstract] [Full Text] [Related]
25. Cytoxan as an adjuvant to surgery for lung cancer.
Higgins GA; Humphrey EW; Hughes FA; Keehn RJ
J Surg Oncol; 1969; 1(3):221-8. PubMed ID: 5406365
[No Abstract] [Full Text] [Related]
26. Guidelines for management of lung cancer.
Blair C; Butler C; Cotman HE; Lloyd R; Lundell D; McMahon L
Ariz Med; 1977 Mar; 34(3):176-82. PubMed ID: 194553
[No Abstract] [Full Text] [Related]
27. Bronchogenic carcinoma: a plea for conservative management.
Patton AJ; Kardinal CG
Mo Med; 1977 Jan; 74(1):19-20, 22, 28. PubMed ID: 834165
[No Abstract] [Full Text] [Related]
28. How to deal with bronchogenic carcinoma in the elderly.
Ross WM
Geriatrics; 1976 Jun; 31(6):107-10. PubMed ID: 58805
[No Abstract] [Full Text] [Related]
29. Study of methyl-CCNU(NSC-95441) in the treatment of lung cancer.
Richards F; Pajak TF; Cooper MR; Spurr CL
Cancer Chemother Rep; 1973; 57(4):419-22. PubMed ID: 4357670
[No Abstract] [Full Text] [Related]
30. Expectoration of bronchogenic tumour tissue.
Kaira K; Shimizu Y; Sunaga N; Hisada T; Ishizuka T; Mori M
Intern Med J; 2007 May; 37(5):340-2. PubMed ID: 17504286
[No Abstract] [Full Text] [Related]
31. Guest editorial: Lung cancer: a status report.
Cohen MH
J Natl Cancer Inst; 1975 Sep; 55(3):505-11. PubMed ID: 1099219
[No Abstract] [Full Text] [Related]
32. [Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma].
Rebattu P; Coudert B; Schneider M; Ouabdesselam R; Lentz M; Hanauske A; Chevallierdagger B; Fumoleau P; Chollet P
Rev Pneumol Clin; 2000 Jun; 56(3):200-3. PubMed ID: 10880946
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of the effect of methyl-CCNU (NSC-95441) on bronchogenic carcinoma.
Takita H; Brugarolas A; Mittelman A; Vincent R
Cancer Chemother Rep 3; 1973 Mar; 4(2):257-9. PubMed ID: 4125743
[No Abstract] [Full Text] [Related]
34. [Diagnostic strategies in bronchial carcinoma].
Feddersen CO; von Wichert P
Internist (Berl); 1994 Aug; 35(8):724-9. PubMed ID: 7960552
[No Abstract] [Full Text] [Related]
35. Advances in small cell bronchogenic carcinoma.
Bunn PA; Cohen MH; Ihde DC; Fossieck BE; Matthews MJ; Minna JD
Cancer Treat Rep; 1977; 61(3):333-42. PubMed ID: 194690
[No Abstract] [Full Text] [Related]
36. BCNU (NSC-409962) in the treatment of bronchogenic carcinoma.
Whittington RM; Fairly JL; Majima H; Patno ME; Prentice R
Cancer Chemother Rep; 1972 Dec; 56(6):739-43. PubMed ID: 4574055
[No Abstract] [Full Text] [Related]
37. Keynote address on chemotherapy for lung cancer.
Hansen HH
Cancer Chemother Rep 3; 1973 Mar; 4(2):25-8. PubMed ID: 4729326
[No Abstract] [Full Text] [Related]
38. Treatment of modified Stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach.
Newman SB; DeMeester TR; Golomb HM; Hoffman PC; Little AG; Raghavan V
J Thorac Cardiovasc Surg; 1983 Aug; 86(2):180-5. PubMed ID: 6308356
[TBL] [Abstract][Full Text] [Related]
39. [Adjuvant therapy in Operable non-small cell lung cancer].
Joss R; Bleher EA; Goldhirsch A; Kaufmann M; Brunner KW
Schweiz Rundsch Med Prax; 1983 Apr; 72(16):553-60. PubMed ID: 6866936
[No Abstract] [Full Text] [Related]
40. High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial.
Pannuti F; Lelli G; Casadio M; Piana E; Di Marco AR
Cancer Treat Rep; 1980; 64(10-11):1131-4. PubMed ID: 7459899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
